Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Gaboxadol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ovid pens deal to offload twice-failed former lead program
    Ovid pens deal to offload twice-failed former lead program

    09 Feb 2022

    // H. Shasteen BIOSPACE

    https://www.biospace.com/article/healx-and-ovid-therapeutics-enter-partnership-for-fragile-x-therapy/

    H. Shasteen BIOSPACE
    09 Feb 2022
    Share Share
    Ovid's Angelman syndrome therapy falls short at Phase 3
    Ovid's Angelman syndrome therapy falls short at Phase 3

    02 Dec 2020

    // PHARMAFILE

    http://www.pharmafile.com/news/565290/ovids-angelman-syndrome-therapy-falls-short-phase-3

    PHARMAFILE
    02 Dec 2020
    Share Share
    Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020
    Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020

    23 Nov 2020

    // PRESSRELEASE

    https://investors.ovidrx.com/news-releases/news-release-details/ovid-therapeutics-present-american-epilepsy-society-aes-2020

    PRESSRELEASE
    23 Nov 2020
    Share Share
    Angelini lands EU rights to Ovid's phase 3 rare disease drug
    Angelini lands EU rights to Ovid's phase 3 rare disease drug

    14 Jul 2020

    // Nick P Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/angelini-lands-eu-rights-to-ovid-s-phase-3-rare-disease-drug

    Nick P Taylor FIERCE BIOTECH
    14 Jul 2020
    Share Share
    Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101
    Ovid Therapeutics Announces +ve Topline Results from Ph2 ROCKET Trial of OV101

    08 May 2020

    // PRESS RELEASE

    https://investors.ovidrx.com/news-releases/news-release-details/ovid-therapeutics-announces-positive-topline-results-phase-2

    PRESS RELEASE
    08 May 2020
    Share Share